1. Waldenstr�m's macroglobulinemia
- Author
-
James D. Cotelingam, Jo-Ann W. Andriko, Meenakshi A. Nandedkar, Nadine S. Ives Aguilera, and Wei S. Chu
- Subjects
Cancer Research ,Cytopenia ,Pathology ,medicine.medical_specialty ,business.industry ,Chronic lymphocytic leukemia ,Macroglobulinemia ,Waldenstrom macroglobulinemia ,medicine.disease ,Richter's transformation ,Immunophenotyping ,medicine.anatomical_structure ,Oncology ,medicine ,Bone marrow ,business ,Multiple myeloma - Abstract
BACKGROUND Waldenstrom's macroglobulinemia (WM) is a rare immunoproliferative disorder, the clinical course of which varies. In related B-cell neoplasms, such as multiple myeloma and chronic lymphocytic leukemia, the histologic features of bone marrow are considered to be of prognostic relevance. METHODS To assess the prognostic features of WM, the authors reviewed the clinical and pathologic features of 22 patients. Bone marrow aspirates and core biopsies were available for each case. Immunostains for a panel of hematopoietic markers as well as p53 and proliferating cell nuclear antigen (PCNA) were performed. RESULTS There were 14 males and 8 females, with a mean age of 60 years. At presentation, two histologic subtypes, lymphoplasmacytoid (73%) and lymphoplasmacytic (27%), were observed. Four patterns of bone marrow infiltration were delineated: diffuse (45%), nodular-interstitial (22%), mixed paratrabecular-nodular (20%), and paratrabecular (13%). In 11 patients, the infiltrate occupied greater than 70% of the bone marrow; in 8 patients, 30-70%; and in 3 patients, less than 30%. PCNA reactivity was observed in 58% of cases and p53 reactivity in 21%. Ten patients died of disease with an average survival of 84 months. The remaining 12 patients were alive with disease at last follow-up. The pretreatment parameters that were correlated with shorter survival were hemoglobin, white blood cell count, platelet count, splenomegaly, lymphadenopathy, and serum immunoglobulin M level. CONCLUSIONS The findings of this study suggest that some pretreatment parameters, such as cytopenia, serum immunoglobulin M level, splenomegaly, and lymphadenopathy, correlate with poor prognosis for patients with WM. In contrast, histologic features and expression of p53 and PCNA did not correlate significantly with survival. Cancer 1997; 80:1926-35. © 1997 American Cancer Society.
- Published
- 1997